DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 2035-2043

  Moeller, Benjamin J ^a   Yordy, John S ^a   Williams, Michelle D ^a   Giri, Uma ^a   Raju, Uma ^a   Molkentine, David P ^a   Byers, Lauren A ^a   Heymach, John V ^a   Story, Michael D ^b   Lee, J Jack ^a   Sturgis, Erich M ^a   Weber, Randal S ^a   Garden, Adam S ^a   Ang, K Kian ^a   Schwartz, David L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; CISPLATIN; DNA; PROTEIN KU80; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; COHORT ANALYSIS; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; FEMALE; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TISSUE MICROARRAY; TREATMENT FAILURE; TREATMENT OUTCOME; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; DNA BREAKS, DOUBLE-STRANDED; DNA HELICASES; DNA REPAIR; DNA REPAIR ENZYMES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROTEIN ARRAY ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79953306841     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2641     Document Type: Article

References (33)

1. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76. (Pubitemid 41095116)
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78. (Pubitemid 43209104)
3. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-64. (Pubitemid 30205391)
4. Cooper JS, Farnan NC, Asbell SO, Rotman M, Marcial V, Fu KK, et al. Recursive partitioning analysis of 2105 patients treated in Radiation Therapy Oncology Group studies of head and neck cancer. Cancer 1996;77:1905-11. (Pubitemid 26125194)
5. Leon X, Gich I, Orus C, Del Prado Venegas M, Ramon Gras J, Quer M. Comparison of the Radiation Therapy Oncology Group recursive partitioning classification and Union Internationale Contre le Cancer TNM classification for patients with head and neck carcinoma. Head Neck 2005;27:248-57.
6. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20. (Pubitemid 351480511)
7. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-37.
8. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human Papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
9. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
10. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, et al. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007;13:3855-9. (Pubitemid 47037591)
11. Hall E, Giaccia A. Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
12. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007;316:1160-6. (Pubitemid 46877472)
13. Pan X, Ye P, Yuan DS, Wang X, Bader JS, Boeke JD. A DNA integrity network in the yeast Saccharomyces cerevisiae. Cell 2006;124:1069-81. (Pubitemid 43344244)
14. Dabaja B, Salehpour MR, Rosen I, Tung S, Morrison WH, Ang KK, et al. Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: comparison of split-field and whole-field techniques. Int J Radiat Oncol Biol Phys 2005;63:1000-5. (Pubitemid 41505275)
15. Garden AS, Morrison WH, Wong PF, Tung SS, Rosenthal DI, Dong L, et al. Disease-control rates following intensity-modulated radiation therapy for small primary oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2007;67:438-44. (Pubitemid 46108322)
16. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, et al. Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys 2010;78:667-74.
17. Pepe MS, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?Stat Med 1993;12:737-51.
18. Friesland S, Kanter-Lewensohn L, Tell R, Munck-Wikland E, Lewensohn R, Nilsson A. Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy. Head Neck 2003;25:313-21. (Pubitemid 36368683)
19. Lee SW, Cho KJ, Park JH, Kim SY, Nam SY, Lee BJ, et al. Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol, Biol, Phys 2005;62:1451-7.
20. Pavón MA, Parreño M, León X, Sancho FJ, Céspedes MV, Casanova I, et al. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer. Int J Cancer 2008;123:1068-79.
21. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 2009;417:639-50.
22. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem 2008;8:448-60. (Pubitemid 351761429)
23. Collis SJ, DeWeese TL, Jeggo PA, Parker AR. The life and death of DNA-PK. Oncogene 2005;24:949-61. (Pubitemid 40313872)
24. Chang HW, Kim SY, Yi SL, Son SH, Song do Y, Moon SY, et al. Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol 2006;42:979-86.
25. Nimura Y, Kawata T, Uzawa K, Okamura J, Liu C, Saito M, et al. Silencing Ku80 using small interfering RNA enhanced radiation sensitivity in vitro and in vivo. Int J Oncol 2007;30:1477-84.
26. Kim SH, Kim D, Han JS, Jeong CS, Chung BS, Kang CD, et al. Ku autoantigen affects the susceptibility to anticancer drugs. Cancer Res 1999;59:4012-7. (Pubitemid 29393570)
27. Silva P, Slevin NJ, Sloan P, Valentine H, Cresswell J, Ryder D, et al. Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer. Int J Radiat Oncol, Biol, Phys 2008;72:1551-9.
28. Le QT, Kong C, Lavori PW, O'byrne K, Erler JT, Huang X, et al. Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol, Biol, Phys 2007;69:167-75. (Pubitemid 47247510)
29. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489-500. (Pubitemid 38610250)
30. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66:8210-8. (Pubitemid 44299189)
31. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21. (Pubitemid 40559006)
32. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7. (Pubitemid 40559005)
33. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.